A Pharmacokinetic and Safety Study of CSTI-500 in Subjects With Prader-Willi Syndrome
Status:
Not yet recruiting
Trial end date:
2023-01-15
Target enrollment:
Participant gender:
Summary
The purpose of this Phase 1 study is to evaluate the pharmacokinetics (PK) and safety of a
single dose of CSTI-500 10 mg in subjects with Prader-Willi syndrome (PWS) between 13 and 50
years of age with a genetically confirmed diagnosis of PWS.